HBV Infection-Induced Liver Cirrhosis Development in Dual-Humanised Mice with Human Bone Mesenchymal Stem Cell Transplantation
Lunzhi Yuan,Jing Jiang,Xuan Liu,Yali Zhang,Liang Zhang,Jiaojiao Xin,Kun Wu,Xiaoling Li,Jiali Cao,Xueran Guo,Dongyan Shi,Jun Li,Longyan Jiang,Suwan Sun,Tengyun Wang,Wangheng Hou,Tianying Zhang,Hua Zhu,Jun Zhang,Quan Yuan,Tong Cheng,Ningshao Xia
DOI: https://doi.org/10.1136/gutjnl-2018-316091
IF: 24.5
2019-01-01
Gut
Abstract:Objective Developing a small animal model that accurately delineates the natural history of hepatitis B virus (HBV) infection and immunopathophysiology is necessary to clarify the mechanisms of host-virus interactions and to identify intervention strategies for HBV-related liver diseases. This study aimed to develop an HBV-induced chronic hepatitis and cirrhosis mouse model through transplantation of human bone marrow mesenchymal stem cells (hBMSCs). Design Transplantation of hBMSCs into Fah -/- Rag2 -/- IL-2Rγc -/- SCID (FRGS) mice with fulminant hepatic failure (FHF) induced by hamster-anti-mouse CD95 antibody JO2 generated a liver and immune cell dual-humanised (hBMSC-FRGS) mouse. The generated hBMSC-FRGS mice were subjected to assessments of sustained viremia, specific immune and inflammatory responses and liver pathophysiological injury to characterise the progression of chronic hepatitis and cirrhosis after HBV infection. Results The implantation of hBMSCs rescued FHF mice, as demonstrated by robust proliferation and transdifferentiation of functional human hepatocytes and multiple immune cell lineages, including B cells, T cells, natural killer cells, dendritic cells and macrophages. After HBV infection, the hBMSC-FRGS mice developed sustained viremia and specific immune and inflammatory responses and showed progression to chronic hepatitis and liver cirrhosis at a frequency of 55% after 54 weeks. Conclusion This new humanised mouse model recapitulates the liver cirrhosis induced by human HBV infection, thus providing research opportunities for understanding viral immune pathophysiology and testing antiviral therapies in vivo.